Business
VYNE Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
IND clearance received for pan-BD BET inhibitor, VYN201; Anticipate first patient to be enrolled in Phase 1a/b trial for Vitiligo this month Continued
About this update from Vyne Therapeutics Inc.
[{"type":"text","content":"IND clearance received for pan-BD BET inhibitor, VYN201; Anticipate first patient to be enrolled in Phase 1a/b trial for Vitiligo this month Continued progression of discovery and development of oral, BD2 selective VYN202 program Expanded analysis of FMX114 Phase 2a trial results suggests FMX114 may have the potential to effectively treat patients with moderate-to-severe atopic dermatitis; VYNE currently evaluating development strategy for FMX114 BRIDGEWATER, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and nine months ended September 30, 2022. “The third quarter was pivotal for VYNE as we advanced toward the first clinical trial for our InhiBET™ BET inhibitor platform,” said David Domzalski, President and Chief Executive Officer of VYNE. “We anticipate enrolling the first patient in our Phase 1a/b trial evaluating our pan-BD BET inhibitor, VYN201, in vitiligo this month and look forward to reporting topline results in healthy volunteers and vitiligo patients in the first half of 2023. In addition, we have made considerable progress in the discovery and development of lead candidates for the VYN202 program with our partner, Tay Therapeutics (formerly In4Derm). Finally, we completed further analyses on the Phase 2a data for FMX114 which showed that while efficacy results were not statistically significant at week 4, the results were statistically superior at all other time points including weeks 1, 2, and 3. Additionally, efficacy results continued to develop beyond week 4 throughout the open-label extension, and the overall treatment effect of FMX114 as compared to vehicle increased when treating more severe disease. We will continue to evaluate our development strategy for FMX114.” Pipeline Update VYN201 -- VYN201 is a locally administered, small molecule, pan-bromodomain and extra-terminal domain (\"BET\") inhibitor (\"BETi\") that is being developed for the treatment of immuno-inflammatory diseases. VYNE expects to enroll the first patient in a Phase 1a/b clinical trial designed to generate safety and pharmacokinetic data in healthy volunteers as well as provide ear...